Drug Profile
Insulin 338
Alternative Names: Insulin oral (NN 1953); Insulin-338-GIPET-I; LAI 338; NN 1438; NN-1953; NNC-0123-0000-0338; NNC0123-0338; OI-338GT; Oral insulin 338 C10Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Class Antihyperglycaemics; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Type 1 diabetes mellitus; Type 2 diabetes mellitus
Highest Development Phases
- Phase II Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus in Germany (SC, Injection)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in Denmark (SC, Injection)
- 11 Sep 2017 Efficacy and adverse events data from a phase II trial in Type-2 diabetes mellitus presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD-2017)